PL3444349T3 - Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach - Google Patents

Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach

Info

Publication number
PL3444349T3
PL3444349T3 PL18183735T PL18183735T PL3444349T3 PL 3444349 T3 PL3444349 T3 PL 3444349T3 PL 18183735 T PL18183735 T PL 18183735T PL 18183735 T PL18183735 T PL 18183735T PL 3444349 T3 PL3444349 T3 PL 3444349T3
Authority
PL
Poland
Prior art keywords
island
organs
prevention
compositions
methods
Prior art date
Application number
PL18183735T
Other languages
English (en)
Inventor
Elizabeth C. Squiers
Shai Erlich
Daniel ROTHENSTEIN
Nir Sharon
Daniel J. ODENHEIMER
Elena Feinstein
Original Assignee
Quark Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals, Inc. filed Critical Quark Pharmaceuticals, Inc.
Publication of PL3444349T3 publication Critical patent/PL3444349T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18183735T 2014-05-29 2015-05-27 Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach PL3444349T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462004239P 2014-05-29 2014-05-29
PCT/US2015/032499 WO2015183842A1 (en) 2014-05-29 2015-05-27 Methods and compositions for preventing ischemia reperfusion injury in organs
EP18183735.2A EP3444349B1 (en) 2014-05-29 2015-05-27 Methods and compositions for preventing ischemia reperfusion injury in organs
EP15729289.7A EP3149172B1 (en) 2014-05-29 2015-05-27 Methods and compositions for preventing ischemia reperfusion injury in organs

Publications (1)

Publication Number Publication Date
PL3444349T3 true PL3444349T3 (pl) 2021-06-28

Family

ID=53398201

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15729289T PL3149172T3 (pl) 2014-05-29 2015-05-27 Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach
PL18183735T PL3444349T3 (pl) 2014-05-29 2015-05-27 Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15729289T PL3149172T3 (pl) 2014-05-29 2015-05-27 Sposoby i kompozycje do zapobiegania urazom niedokrwienno-reperfuzyjnym w narządach

Country Status (18)

Country Link
US (3) US20170081665A1 (pl)
EP (2) EP3149172B1 (pl)
JP (2) JP2017521374A (pl)
KR (1) KR20170007492A (pl)
CN (2) CN106661579B (pl)
AU (1) AU2015267160B2 (pl)
BR (1) BR112016028009A2 (pl)
CA (1) CA2949109A1 (pl)
DK (2) DK3149172T3 (pl)
ES (2) ES2862185T3 (pl)
HU (2) HUE040092T2 (pl)
IL (2) IL248912A0 (pl)
LT (2) LT3444349T (pl)
MX (2) MX373950B (pl)
PL (2) PL3149172T3 (pl)
PT (2) PT3444349T (pl)
SI (2) SI3444349T1 (pl)
WO (1) WO2015183842A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
US12091664B2 (en) 2018-01-12 2024-09-17 University Of Massachusetts Methods for preventing graft ischemia reperfusion injury during ex vivo machine perfusion preservation
GB202016863D0 (en) * 2020-10-23 2020-12-09 Causeway Therapeutics Ltd Microrna-29 compounds, compositions and uses in therapy
JP2024539149A (ja) * 2021-12-22 2024-10-28 エヌエー ヴァクシン インスティテュート 虚血・再灌流障害を予防または治療するための組成物及びその用途
KR20240154159A (ko) * 2023-04-17 2024-10-25 재단법인 아산사회복지재단 miR-223을 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물
JP2026518142A (ja) * 2023-05-26 2026-06-04 アブレキサ ファーマスーティカルズ,インコーポレイテッド 臓器保存および臓器移植に使用するための化合物
CN118460648B (zh) * 2024-07-10 2025-01-28 凯莱英医药集团(天津)股份有限公司 一种qpi-1002的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
IE920562A1 (en) 1991-02-21 1992-08-26 Gilead Sciences Aptamer specific for biomolecules and method of making
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
EP1143943B1 (en) 1999-01-29 2007-12-12 The Board Of Trustees Of The University Of Illinois USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS OF CANCER THERAPY
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
WO2005111238A2 (en) 2004-04-19 2005-11-24 Archemix Corporation Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
JP4991547B2 (ja) * 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド 脱毛症、急性腎不全および他の疾患の治療のためのオリゴリボヌクレオチドおよびその使用の方法
US8362229B2 (en) 2006-02-08 2013-01-29 Quark Pharmaceuticals, Inc. Tandem siRNAS
US7910566B2 (en) * 2006-03-09 2011-03-22 Quark Pharmaceuticals Inc. Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
SI2170403T1 (sl) 2007-06-27 2014-07-31 Quark Pharmaceuticals, Inc. Sestavki in postopki za inhibicijo ekspresije pro-apoptotskih genov
CA2701845A1 (en) * 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
US8722638B2 (en) * 2008-06-20 2014-05-13 Children's Medical Center Corporation Methods for the modulation of angiogenesis
EP2440214A4 (en) 2009-06-08 2013-07-31 Quark Pharmaceuticals Inc METHOD FOR THE TREATMENT OF CHRONIC KIDNEY DISEASES
TW201124160A (en) 2009-11-26 2011-07-16 Quark Pharmaceuticals Inc SiRNA compounds comprising terminal substitutions
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
WO2011138966A1 (ja) 2010-05-06 2011-11-10 ダイヤニトリックス株式会社 微生物触媒を用いたアクリルアミドの製造方法
WO2012068381A2 (en) * 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
CA2818024C (en) 2010-12-06 2019-09-24 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising positional modifications
US9176487B2 (en) * 2011-10-24 2015-11-03 Mayo Foundation For Medical Education And Research Methods and materials for reducing the risk of infections
EP2895608B1 (en) * 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof

Also Published As

Publication number Publication date
HUE054226T2 (hu) 2021-08-30
WO2015183842A1 (en) 2015-12-03
MX2020005794A (es) 2020-10-28
PT3444349T (pt) 2021-04-06
EP3149172B1 (en) 2018-07-18
CN106661579A (zh) 2017-05-10
EP3149172A1 (en) 2017-04-05
LT3149172T (lt) 2018-09-10
DK3149172T3 (en) 2018-08-20
IL278144A (en) 2020-11-30
MX2016015635A (es) 2017-04-25
AU2015267160A1 (en) 2016-12-01
US20170081665A1 (en) 2017-03-23
IL248912A0 (en) 2017-01-31
US20180305696A1 (en) 2018-10-25
SI3444349T1 (sl) 2021-07-30
DK3444349T3 (da) 2021-04-12
LT3444349T (lt) 2021-04-12
BR112016028009A2 (pt) 2018-02-20
JP2020128383A (ja) 2020-08-27
AU2015267160B2 (en) 2021-07-29
JP2017521374A (ja) 2017-08-03
ES2683869T3 (es) 2018-09-28
IL278144B (en) 2021-07-29
AU2015267160A8 (en) 2016-12-08
HUE040092T2 (hu) 2019-02-28
CA2949109A1 (en) 2015-12-03
US20170335327A1 (en) 2017-11-23
EP3444349A1 (en) 2019-02-20
US9868953B2 (en) 2018-01-16
KR20170007492A (ko) 2017-01-18
SI3149172T1 (sl) 2018-10-30
CN106661579B (zh) 2020-12-04
MX373950B (es) 2020-07-13
EP3444349B1 (en) 2021-01-06
ES2862185T3 (es) 2021-10-07
PT3149172T (pt) 2018-10-08
CN112410336A (zh) 2021-02-26
PL3149172T3 (pl) 2018-10-31

Similar Documents

Publication Publication Date Title
IL287952A (en) Compositions and methods for non-myeloablative conditioning
IL259795A (en) Methods and compositions for treating a serpinc1-associated disorder
IL266458A (en) Equipment and methods for treating objects
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
PL3212225T3 (pl) Sposoby i kompozycje zmodyfikowanych limfocytów t
DK3145493T3 (da) Fremgangsmåder og sammensætninger vedrørende exosomer
HUE053485T2 (hu) Készítmények és eljárások meibom-mirigy diszfunkció kezelésére
ZA201700241B (en) Mnk inhibitors and methods related thereto
HUE052095T2 (hu) Keratin kezelési készítmények és eljárások
PL3189074T3 (pl) Kompozycje oraz sposoby leczenia i zapobiegania zapaleniom
KR20180084891A (ko) 구조 조성물 및 방법
BR112017011771A2 (pt) métodos e composições para o tratamento de câncer
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
IL255307B (en) Tpp1 formulations and uses thereon in cln2 disease
MA41794A (fr) Agents thérapeutiques modifiés et compositions associées
DK3194564T3 (da) Trichodermasammensætninger og anvendelsesfremgangsmåder
EP3310376A4 (en) MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
IL249098A0 (en) Methods and preparations for the treatment of allergy and inflammatory diseases
IL248160A0 (en) Compositions of tissue fillers and methods of use
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
IL251836A0 (en) Compositions and methods for physiological delivery using cannabidiol
EP4043567C0 (en) METHOD AND COMPOSITIONS FOR TREATMENT OF CANCER
LT3324938T (lt) Vietinio veikimo kompozicijos ir gydymo būdai
IL257458B1 (en) Dpep-1 binding compositions and methods of use
PT3149172T (pt) Métodos e composições para prevenção de lesão de isquemia-reperfusão em órgãos